Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial

MLA

Bazinet, Alexandre, et al. “Reduced Dose Azacitidine plus Venetoclax as Maintenance Therapy in Acute Myeloid Leukaemia Following Intensive or Low-Intensity Induction: A Single-Centre, Single-Arm, Phase 2 Trial.” The Lancet Haematology, vol. 11, no. 4, Apr. 2024, pp. e287–98. EBSCOhost, https://doi.org/10.1016/S2352-3026(24)00034-6.

APA

Bazinet, A., Kantarjian, H., Bataller, A., Pemmaraju, N., Borthakur, G., Chien, K., Alvarado, Y., Bose, P., Jabbour, E., Yilmaz, M., DiNardo, C., Issa, G., Montalban-Bravo, G., Short, N., Sasaki, K., Bull-Linderman, D., Daver, N., Garcia-Manero, G., Ravandi, F., & Kadia, T. (2024). Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. The Lancet Haematology, 11(4), e287–e298. https://doi.org/10.1016/S2352-3026(24)00034-6

Chicago

Bazinet, Alexandre, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, et al. 2024. “Reduced Dose Azacitidine plus Venetoclax as Maintenance Therapy in Acute Myeloid Leukaemia Following Intensive or Low-Intensity Induction: A Single-Centre, Single-Arm, Phase 2 Trial.” The Lancet Haematology 11 (4): e287–98. doi:10.1016/S2352-3026(24)00034-6.